Use quotation marks("") to search for exact phrase or group of words
e.g. "breakbone fever"
Use "OR" to get either results
Placing "OR" in between your keywords gives you more results
e.g. dengue OR "breakbone fever"
Use "NOT" to exclude words
e.g. health care service NOT in manila
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years.
To evaluate the safety and tolerability of 40 μg PTX-COVID19-B in healthy seronegative adults 18-64 years of age.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care
Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus)
GlobalSurg-CovidSurg Week: Determining the optimal timing for surgery following SARS-CoV-2 infection – Philippine General Hospital data
30 day Post-operative Mortality
A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Adults ≥ 18 Years Old Who Received 2 or more doses of Inactivated Covid-19 Vaccine
Proportion of participants with resolution of NASH without worsening of liver fibrosis based on biopsy at Week 48
Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis
A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety, and tolerability in patients with active lupus nephritis
The primary objective is to assess long-term efficacy of secukinumab with respect to Complete Renal Response (CRR) over time up to Week 260 in adult participants with Lupus Nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) on background SoC therapy
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Suspected or Documented Gram-negative Bacterial Infection
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Multicenter, open-label trial to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) to subjects with IgAN.
Safety and Tolerability
Immunoglobulin A Nephropathy